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Rifaximin has been reported to be effective for the treat-
ment of hepatic encephalopathy (HE) in Europe. However, it
is unknown whether Rifaximin is effective for the treatment
of HE in Koreans, therefore we conducted a open-label pros-
pective randomized study to evaluate the efficacy of rifaximin
versus lactulose in Korean patients. Fifty-four patients with
liver cirrhosis and hepatic encephalopathy were enrolled.
Thirty-two patients were randomized to receive rifaximin and
22 to receive lactulose both over a 7-day periods. Before and
at the end of treatment, gradation of blood ammonia, flapping
tremor, mental status, number connection test (NCT) were
performed and estimation of HE indexes determined. Both
rifaximin and lactulose were effective in the majority of
patients (84.4% and 95.4%, respectively, p=0.315). Blood
NH3, flapping tremor, mental status, and NCT was signifi-
cantly improved by rifaximin and lactulose, and the post-
treatment levels of these measures were similar for the
rifaximin and lactulose-treated groups, as was the HE index
(rifaximin group (10.0 4.2, p=0.000); lactulose group (11.3
5.0, p=0.000)). One patient treated with rifaximin com-
plained of abdominal pain, which was easily controlled.
There was no episode of renal function impairment in either
treatment group. Rifaximin proved to be as safe and as effec-
tive as lactulose for the treatment of Korean patients with
hepatic encephalopathy.
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INTRODUCTION
Hepatic encephalopathy (HE) is presented clini-
cally as a combination of neuropsychiatric abnor-
malities characterized by alterations in mental
status, personality, intellectual function, and
changes in neuromuscular activity. It is frequently
observed in those with both acute liver failure and
liver cirrhosis.
1 The pathogenesis of the syndrome
is complex, but ammonia produced by intestinal
bacteria is known to play an important role in its
pathogenesis. The treatment of HE has focused on
reducing both the production and absorption of
gut-derived ammonia. Presently, non-absorbable
disaccharides and antibiotics are the mainstay of
therapy.
2,3 However, currently used drugs have
several limitations. For example, neomycin, a
poorly-absorbed aminoglycoside may cause ne-
phrotoxicity and ototoxicity,
3 and lactulose treat-
ment may be complicated by excessive diarrhea
and abdominal pain.
4,5
Rifaximin (4-deoxy-4'-methylpyrido-(1',2'-1,2)-
imidazo-(5,4C)-rifamycin SV) is a derivative of
rifamycin, which acts by inhibiting bacterial ribo-
nucleic acid (RNA) synthesis. Rifaximin is vir-
tually unabsorbed after oral administration and
exhibits broad spectrum antimicrobial activity
against both aerobic and anaerobic gram-positive
and gram-negative microorganisms within the
gastrointestinal tract.
6 During the past decade,
several European studies have proved the efficacy
of rifaximin for the treatment of HE in Caucasian
patients.
7-14 However, no similar investigation has
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been performed in Asian patients.
It has been reported that ethnicity can affect
therapeutic response to anti-viral therapies and
the long-term prognosis of patients with advanced
liver diseases.
15-17 In particular, it is not known
whether ethnic background affects the effective-
ness of rifaximin in the treatment of HE. In Korea,
hepatitis B is the major cause of decompensated
liver cirrhosis presenting hepatic encephalopathy,
in contrast, in Western countries, liver cirrhosis
secondary to alcohol abuse predominates.
18,19
Alcohol overdose often leads to intestinal bacterial
overgrowth which is one of the important precipi-
tating factors of HE.
20 Thus etiologic differences
may affect the therapeutic efficacy of rifaximin in
Korean patients with HE. Therefore, we con-
ducted this prospective, randomized study to
determine the efficacy and tolerability of rifaximin
versus lactulose for the treatment of HE in Korean
patients.
MATERIALS AND METHODS
Patients
Sixty-four in-patients with episodic HE who
were admitted at Yonsei University Medical
Center (Seoul, Korea) were firstly enrolled in the
study. All patients were affected by decompen-
sated liver cirrhosis and HE, which were diag-
nosed based on clinical and laboratory findings.
Patients showed signs of the first to third degree
HE, according to Conn's modification of Parsons-
Smith classification,
21 and had serum ammonia
levels > 75 μmol/L.
The criteria for exclusion from the study were:
an age <18 years, the presence of a major neuro-
psychiatric illness, presence of intestinal obstruc-
tion or inflammatory bowel disease, hypersensi-
tivity to rifamycin or disaccharides, a serum creat-
inine level>twice normal, those that had received
loop diuretics, antacids or cathartics within the 12
hour period preceding study commencement,
patients that were on antibiotics during the
preceding 7 days, and those that had been treated
with encephalopathy-causing agents. Women of
child-bearing age were excluded if they were not
using a method of contraception.
Ten of the 64 initially enrolled patients were
excluded, and 54 patients finally entered the trial.
The enrolled patients were 37 males and 17
females, aged between 40 and 71 (mean age 55.7
years). At the start of the study, the demographic
and clinical parameters of the patients in the two
groups showed no significant differences (Table
1). Identified precipitating factors included dehy-
dration (n=14), protein overload (n=13), constipa-
tion (n=12), bacterial infection (n=3), and un-
known (n=12). There was no significant difference
Table 1. Clinical and Laboratory Characteristics of the Patients
Rifaximin (n=32) Lactulose (n=22) p-value
Age 56.2 ± 7.1 54.9 ± 6.6 0.663
Sex (M:F) 24:8 13:9 0.327
Cause of liver disease
(HBV/HCV/alcohol) 26/3/3 15/1/6 0.201
Child-Pugh class (A/B/C) 0/16/16 0/14/8 0.407
Albumin (g/dL) 2.8 ± 0.5 3.1 ± 0.5 0.105
Bilirubin (mg/dL) 5.9 ± 5.2 5.1 ± 6.1 0.658
Platelet (× 10
3/μL) 77.0 ± 37.3 66.3 ± 29.8 0.271
Hematocrit (%) 31.7 ± 4.8 31.2 ± 5.2 0.761
BUN (mg/dL) 18.1 ± 13.1 15.0 ± 6.9 0.301
Creatinine (mg/dL) 0.97 ± 0.44 0.87 ± 0.25 0.373
NH3 (μmol/L) 192.7 ± 63.4 204.0 ± 67.5 0.707
mean ± SD.Rifaximin Versus Lactulose for Hepatic Encephalopathy
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between the two groups in terms of factors pre-
cipitating HE (Table 2).
The research was performed in accordance with
the revised Helsinki Declaration, and the study
protocol adopted was approved by the Yonsei
University Medical Center Institutional Ethics
Committee. The protocol was explained to at least
one relative of each patient selected for the study,
and written informed consent was obtained from
all patients who participated or from their rela-
tives.
Drug Administration
Using a computer-generated sequential 3:2
block randomization list, patients were assigned
to receive rifaximin (Normix , Alfa Farmaceutici
SpA, Bologna, Italy) at 1200 mg per day in three
divided doses (n=32) or lactulose (Duphalac syrup
, Choongwae Pharmaceutical, Seoul, Korea) at 90
mL a day (n=22). The treatment duration was 7
days unless symptoms worsened or serious side
effects occurred. All patients were given a nutri-
tious diet containing a maximum of 40g of protein
per day. At the beginning of the trial, patients
underwent a full assessment, including a detailed
history taking, and physical and neurological ex-
aminations. The following parameters were evalu-
ated before and at the end of the treatment period:
complete blood count, blood chemistry, serum
electrolytes, renal function, blood sugar, and uri-
nalysis. Adverse events were assessed by the
investigators. Any abnormal clinical or laboratory
findings observed during the trial were monitored
and documented. Drug administration was dis-
continued in the event of 1) severe side effect, 2)
taking any medication that could potentially inter-
fere with the course of HE, 3) a serious cirrhotic
complication such as acute variceal bleeding, or
spontaneous bacterial peritonitis, and 4) a
patient's refusal to participate in the trial.
Grade of mental state
This was examined semi-quantitatively using
Conn's modification of the Parsons-Smith classifi-
cation.
21 Grade 0: no abnormality; Grade 1: trivial
loss of awareness, euphoria or anxiety, shortened
attention span, impairment of addition or subtrac-
tion performance; Grade 2: lethargy, disorienta-
tion with respect to time, obvious personality
change, inappropriate behavior; Grade 3: som-
nolence to semi-stupor, responsive to stimuli, con-
fusion, gross disorientation, bizarre behavior; and
Grade 4: coma, unable to test mental function.
Table 2. Hepatic Encephalopathy Related Factors of the Patients
Rifaximin (n=32) Lactulose (n=22) p-value
Baseline mental state
(grade 0/ 1/ 2/ 3/ 4) 0/ 24/ 5 /3/ 0 0/ 14/ 4/ 4/ 0 0.586
Precipitating factors of HE
dehydration 9 (28.1%) 5 (22.7%) 0.941
protein overload 8 (25.0%) 5 (22.7%)
constipation 6 (18.8%) 6 (27.3%)
bacterial infection 2 (6.3%) 1 (4.5%)
unknown 7 (21.9%) 5 (22.7%)
Episode of HE
acute 13 (40.6%) 13 (59.1%) 0.182
recurrent 19 (59.4%) 9 (40.9%)
Ascites
present 24 (75.0%) 13 (59.1%) 0.216
Splenomegaly
present 22 (68.8%) 18 (81.8%) 0.282Yong-Han Paik, et al.
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The severity of flapping tremor
Severity was determined by extending the pa-
tients' arms and forearms with the wrists dorsi-
flexed for at least 30 seconds. We adopted a
simplified grading system to minimize inter-ob-
server variance. Grade 0: no flapping motion;
Grade 1: infrequent flapping motion; Grade 2:
continual flapping motion; and Grade 3: unable to
test.
Number connection test (NCT)
The time taken to connect 25 progressive num-
bers, i.e. part A of the number connection test.
22,23
Grade 0: < 30 sec (normal); Grade 1: 31-50 sec;
Grade 2: 51-80 sec; Grade 3: 81-120 sec; and Grade
4: > 120 sec.
Blood ammonia levels
Blood ammonia was measured before and after
the treatment using Cobas Integra 800 (Roche,
Basel, Switzerland). Grade 0: < 75 μM/L; Grade 1:
76-150 μM/L; Grade 2: 151-200 μM/L; Grade 3:
201-250 μM/L; and Grade 4: > 251 μM/L.
HE index
The above items were determined before treat-
ment and on days 3, 5, 7 of the trial period. The
grades for the above four components were
weighted in proportion to their importance. Thus,
HE grade awarded a weighting factor of three,
while the other variables were each assigned a
factor of one. The HE index was defined as the
total of the weighted grades, and had a possible
range of 0 to 23 points, i.e., HE index=(grade of
mental state) ×3+(grade of number connection test)
+(grade of flapping tremor)+(grade of blood am-
monia).
21
Efficacy of treatment
Efficacy was graded as 'improved', 'unchanged',
or 'worsened'. A decrease of HE index by at least
one point was defined as 'improved', and incre-
ment of the HE index by one point or more was
defined as 'worsened'.
Statistical analysis
All data are expressed as means±SD. Statistical
evaluations were performed using SAS version
6.12 for Windows (SAS Institute Inc., Cary, NC).
Statistical analyses were made using the Student's
T-test, the paired T-test, Fisher's exact test, and the
Chi-square test. This study satisfied a statistical
power of 0.8. A probability level of p < 0.05 was
considered to be significant throughout.
RESULTS
Comparison of therapeutic responses to
rifaximin and lactulose
Table 3 compares the therapeutic effects of
rifaximin and lactulose. Mean blood levels and
grades of blood NH3 significantly decreased with
Table 3. Changes in HE Index and HE-related Parameters after Treatment
Lactulose (n=22) Rifaximin (n=32)
PreTx PostTx p-value PreTx PostTx p-value
Blood NH3 level (mmol/L) 192.7 ± 63.4 128.3 ± 49.1 0.004 204.0 ± 67.5 138.0 ± 60.5 0.008
Blood NH3 grade 1.8 ± 0.9 0.9 ± 0.9 0.000 1.9 ± 0.9 1.0 ± 0.9 0.002
Mental status grade 1.3 ± 0.7 0.3 ± 0.4 0.000 1.5 ± 0.8 0.5 ± 0.7 0.000
Grade of Flapping tremor 1.7 ± 0.8 0.4 ± 0.6 0.000 1.4 ± 0.8 0.3 ± 0.7 0.000
Grade of NCT 3.0 ± 1.0 2.0 ± 1.2 0.000 3.3 ± 0.9 2.1 ± 1.1 0.000
HE index 10.0 ± 3.9 4.2 ± 2.7 0.000 11.3 ± 3.9 5.0 ± 4.1 0.000
HE, hepatic encephalopathy; NCT, number connection test; Tx, treatment. (mean ± SD)Rifaximin Versus Lactulose for Hepatic Encephalopathy
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both rifaximin (p < 0.01) and lactulose treatment (p
< 0.01). Mean blood NH3 concentrations were
similar after both forms of therapy (Fig. 1A).
Mental state was significantly improved by rifaxi-
min (1.3 0.3) and by lactulose (1.5 0.5) (p < 0.01
and p < 0.01, respectively). Grades of flapping
tremor and NCT were improved to nearly equal
degrees by rifaximin and lactulose treatment
(Table 3). Mean HE indexes improved both in the
rifaximin group (10.0 4.2, p=0.000) and in the
lactulose group (11.3 5.0, p=0.000) (Fig. 1B). No
significant difference was found between the two
groups in terms of the grades of HE components
at any given time.
Clinical efficacy
At the completion of treatment, blood NH3 and
HE grades improved in 25 (78.1%) and 26 (81.3%),
respectively, of the 32 patients in the rifaximin
group. In the lactulose group, 13 (59.1%) of the 22
patients showed reduced blood ammonia grades
and 16 cases (72.7%) improved HE grades. These
group differences were not statistically significant
(Table 4). Clinical efficacy was determined using
HE index improvement. Rifaximin was considered
effective in 27 of 32 patients (84.4%) and lactulose
in 21 of 22 patients (95.4%), which was not signi-
ficantly different (p=0.315) (Table 4).
We then compared the clinical characteristics of
patients who showed a HE index improvement
(n=27) with those who did not (n=5) after rifaxi-
min treatment (Table 5). No significant differences
in terms of age, sex, cause of liver disease, Child-
Pugh class, episode of HE, or baseline mental state
was observed between the two groups. Baseline
blood urea nitrogen and creatinine levels were
higher in patients who showed HE improvement
after rifaximin treatment. Interestingly, the base-
line ammonia level and the HE index were higher
in the improvement group than in the no-impro-
vement group after rifaximin treatment (p < 0.05)
(Table 5).
Adverse effects
Overall patient compliance was excellent. One
patient treated with rifaximin complained of ab-
dominal pain, and one patient treated with
lactulose experienced severe diarrhea, but no
patient was withdrawn from the trial due to an
undue adverse effect. Renal function impairment
did not occur in any patient.
Fig. 1. (A) Changes in grade of blood ammonia level with Rifaximin (solid line) or Lactulose (dotted line) treatment. Grade
of blood ammonia was significantly decreased at the end of the treatment with respect to pre-treatment values in both
groups (p < 0.01). (B) Changes in HE index with Rifaximin (solid line) and Lactulose (dotted line) treatment. Marked
improvement in HE index was noted at the end of the treatment (p < 0.01) compared to pre-treatment values in both
groups (p < 0.01).
A BYong-Han Paik, et al.
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DISCUSSION
Although a number of other possible factors
have been proposed to play a role in the patho-
genesis of HE, such as, the production of central
benzodiazepine agonists, endogenous opioids and
false neurotransmitters, ammonia is still viewed
as the key contributor.
2 Thus the mainstay treat-
ment for HE revolves about reducing the pro-
duction and absorption of ammonia in the gut,
and to improve its excretion by drug therapy or
diet modification. Currently, lactulose and non-
absorbable antibiotics are most commonly used
therapeutics to treat HE.
1-3 Several placebo-con-
trolled trials of lactulose have reported no proof
of superiority versus a placebo. However, these
negative results are believed to be due to the
designs of trials, variables of efficacy, and to low
numbers of enrolled patients.
24-27 Lactulose is cur-
rently recommended as the first-line pharma-
cological treatment for HE by the practice guide-
lines proposed by the American College of Gas-
troenterology.
28 However, the use of lactulose may
be associated with nausea, flatulence, abdominal
cramps, severe diarrhea, and dehydration.
4,5,29
Protracted diarrhea may result in hypertonic de-
hydration with hypernatremia, which may aggra-
vate the patient's mental state.
30
Antibiotics are regarded as a therapeutic al-
ternative to nonabsorbable disaccharides for HE
Table 4. Summary of Changes in HE Index, Blood Ammonia and HE Grade after Rifaximin or Lactulose Treatment
in Patients with HE
Rifaximin
(n=32)
Lactulose
(n=22)
p-value
Improvement of blood ammonia 25 (78.1%) 13 (59.1%) 0.132
Improvement of HE grade 26 (81.3%) 16 (72.7%) 0.459
HE Index
Improved 27 (84.4%) 21 (95.4%) 0.315
Unchanged 2 (6.2%) 1 (4.6%)
Worsened 3 (9.4%) 0
Table 5. Comparison of Clinical Parameters between the Patients who Showed Improvement of HE and those who
Did not after Rifaximin Treatment
Improved HE index
(n=27)
unchanged or worsened HE index
(n=5)
p-value
Age 56.8 ± 6.4 52.8 ± 12.9 0.366
Sex (M:F) 20:7 4:1 0.604
Cause of liver disease
(HBV/HCV/alcohol) 22/ 2/ 3 4/ 1/ 0 0.530
Child-Pugh class (A/B/C) 0/ 13/ 14 0/ 3/ 2 1.000
Episode of HE (acute/recurrent) 10/ 17 3/ 2 0.374
BUN (mg/dL) 19.8 ± 13.7 9.3 ± 1.3 0.001
Creatinine (mg/dL) 1.02 ± 0.44 0.66 ± 0.23 0.021
Baseline mental state
(grade 0/ 1/ 2/ 3/ 4) 0/ 19/ 5/ 3/ 0 0/ 5/ 0/ 0/ 0 0.200
Baseline NH3 level (mmol/L) 201.7 ± 73.2 148.8 ± 24.9 0.013
Baseline HE index 11.2 ± 4.0 6.6 ± 2.9 0.023
(mean ± SD)Rifaximin Versus Lactulose for Hepatic Encephalopathy
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treatment.
28 Neomycin is a non-absorbable amino-
glycoside that has also been prescribed for HE,
but its ototoxicity and nephrotoxicity limit its use
in HE.
3 Metronidazole, which differs from neo-
mycin in terms of its bacterial spectrum, also im-
proves HE, however its potentially severe neuro-
toxicity in patients with cirrhosis limits its com-
mon use.
31 Rifaximin is a semi-synthetic derivative
of rifamycin, has broad-spectrum antimicrobial
activity,
6 and is characterized by its non-absor-
bability by the gut.
32 Rifaximin remains in high
concentrations in its active form in the gut and is
excreted in feces without causing significant sys-
temic side effects such as nephrotoxicity.
6 More-
over, Rifaximin has been shown in previous
studies to be effective at reducing HE parameters
in cirrhotics.
7-14 However, most reports on this
subject have emanated from Europe. It has also
been reported that combinatorial rifaximin and
lactulose is superior to combined neomycin and
lactulose for HE treatment.
8 In addition, a recent
randomized, controlled study conducted in Spain
found that rifaximin and lactitol, a nonabsorbable
disaccharide, have similar efficacies for the treat-
ment of acute HE.
14
The present study is the first, prospective ran-
domized study to compare the efficacy of
rifaximin with that of lactulose for the short-term
treatment of HE in Asia. No data is available
upon whether ethnic background affects the effec-
tiveness of rifaximin for the treatment of HE. Our
study confirms that rifaximin is as effective as
lactulose for the treatment of HE in Korean
patients. Administration at 1200 mg per day led to
an objective and significant improvement in men-
tal state, blood ammonia levels, and HE index.
Moreover, no significant difference was found
between rifaximin and lactulose in terms of their
efficacies. These results suggest that ethnic differ-
ences do not significantly affect the efficacy of
rifaximin as a HE treatment. In this study, the fact
that hepatitis B virus is the predominant (75.9%)
cause of HE should be considered. In Western
countries, alcoholic abuse remains the most com-
mon etiology of liver cirrhosis with HE.
18,19 Con-
sidering intestinal bacterial overgrowth due to
alcohol,
20 rifaximin might theoretically be a better
choice in alcoholic HE than in viral hepatitis-
related HE. However, our results are similar to
those of Western studies concerning the efficacy
of rifaximin for the treatment of HE, which sug-
gests that the cause of HE is of secondary impor-
tance when considering rifaximin as a therapeutic
regimen for HE.
When we analyzed the clinical parameters of
patients who showed an improvement with those
who did not after rifaximin treatment, several
factors were found to be significant by univariate
analysis. However, limited patient numbers pre-
vented multivariate analysis. We believe that fur-
ther study of a larger number of patients would
be necessary to identify those factors that deter-
mine responsiveness to rifaximin in HE treatment.
Interestingly, mean baseline ammonia level and
HE index were higher in the improvement group
than in the no-improvement group after rifaximin
treatment, which suggests that rifaximin can be a
first-line choice for the treatment of moderate to
severe grade HE.
The identification and correction of factors pre-
cipitating HE is of primary concern during the
management of HE,
29 because the correction of
such factors usually results in improvement. Thus
patients' precipitating factors should be carefully
considered in any future trial. In our study, most
patients had an identifiable precipitating factor,
and the two treatment groups had reasonably
similar precipitating factors profiles. Therefore, we
believe that any potential bias caused by precipi-
tating factors was minimal in the present study.
Rifaximin was also fairly well tolerated; only one
patient experienced abdominal pain attributed to
the drug. Renal toxicity and other serious side
effects were absent, and no ethnically distinct side
effects were observed.
All HE therapeutic trials can be criticized from
the perspective of evidence-based medicine.
33
Criticisms include the definitions of study end-
points, the treatment of control groups, the proper
quantification of therapeutic effects. Sanaka et al.
prudently described the difficulties of designing
good HE treatment tirals.
34 The mental status eval-
uation system using the portal systemic enceph-
alopathy (PSE) index developed by Conn et al.
21
is currently widely used. However, the Food and
Drug Administration (FDA) strongly objected to
the use of this system and favoured the adoption
of a detailed mental status evaluation system forYong-Han Paik, et al.
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HE.
34
Although the present study has a limitation due
to its being an open-label study, and may not
overcome some of the challenges previously men-
tioned, it shows that rifaximin is as safe and as
effective as lactulose in Korean patients with HE.
Rifaximin offers a useful therapeutic option in
Asian patients with HE who are unable to tolerate
treatment with disaccharides or who have an im-
paired renal function. Further clinical trials using
a new mental state evaluation system, which
satisfies the FDA's requirements is required to
confirm the efficacy of rifaximin for the treatment
of HE.
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